Central Alerting System
View Alert


Originator: MHRA Drug Alerts

From: Himal Makwana

Issue date: 03-Oct-2019 11:16:51

This alert has been issued to:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Trusts (England) - Medical Director
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Chief Executive
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • GP Practices

Action category: Class 4: For information

Title: CLASS 4 DRUG ALERT, FOR INFORMATION / ACTION, PHARMASWISS CESKA REPUBLIKA S.R.O (AN AFFILIATE OF BAUSCH AND LOMB UK LIMITED), EMERADE 150 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE; EMERADE 300 MICROGRAM SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE AND EMERADE 500 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE

Broadcast content: The MHRA has notified Bausch and Lomb UK Limited of reports that Emerade pens have failed to activate. Following discussions with alternative adrenaline auto-injector suppliers there are currently sufficient supplies available to meet demands. However, there are insufficient surplus devices to replace all the Emerade pens that would need to be recalled. Therefore, at present, the MHRA is advising that Emerade devices should not be recalled; this Drug Alert has been classified as 'Class 4, For Information'. Healthcare professionals are asked to asked to highlight the requirement to carry two pens at all times and for patients to be aware of potential activation issues.

Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts


Additional information: GP Practices: please share this alert within your practices to assist the management of patients who use these medicines.
NHS England Regional Offices: please cascade this alert to community pharmacy.


Alert reference: EL (19)A/23

Attachments:
Cascade to:
  • #GP#
  • #ACCIDENTEMERGENCY#
  • #COMMUNITYPHARMACISTS#
  • #DENTISTS#
  • #DISPENSING GP#
  • #OPTOMETRISTS#
  • #NURSES#
  • #HospitalPharmacy#


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency